192725-17-0 | (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$48.00	$34.00
250mg	98%	in stock	$59.00	$42.00
1g	98%	in stock	$203.00	$142.00
5g	98%	in stock	$713.00	$499.00
10g	98%	in stock	$1,179.00	$825.00

Description

• Catalog Number: AB75232
• Chemical Name: (2S)-N-[(2S,4S,5S)-5-[2-(2,6-dimethylphenoxy)acetamido]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
• CAS Number: 192725-17-0
• Molecular Formula: C37H48N4O5
• Molecular Weight: 628.8008
• MDL Number: MFCD22628840
• SMILES: O=C(N[C@H]([C@H](C[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C

Computed Properties

• Complexity: 940
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 46
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 15
• XLogP3: 5.9

Literature

• Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug.

  International journal of pharmaceutics 20161015

• GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

  Journal of virology 20140301

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.

  Antimicrobial agents and chemotherapy 20131201

• Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.

  Bioorganic & medicinal chemistry 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

  Chemistry & biology 20130919

• Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

  AIDS research and human retroviruses 20130501

• GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20130501

• Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.

  Journal of enzyme inhibition and medicinal chemistry 20130201

• In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.

  The Journal of antimicrobial chemotherapy 20130101

• Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.

  Bioorganic & medicinal chemistry letters 20130101

• Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.

  Leukemia & lymphoma 20121201

• Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.

  Proteins 20121201

• Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.

  Antimicrobial agents and chemotherapy 20121101

• Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.

  Phytotherapy research : PTR 20121001

• A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

  AIDS research and human retroviruses 20121001

• Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.

  The Journal of antimicrobial chemotherapy 20121001

• Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20121001

• Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades.

  Health affairs (Project Hope) 20121001

• Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

  AIDS research and human retroviruses 20120901

• Quantized water access to the HIV-1 protease active site as a proposed mechanism for cooperative mutations in drug affinity.

  Biochemistry 20120821

• Impact of food administration on lopinavir-ritonavir bioequivalence studies.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120815

• Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants.

  Journal of clinical pharmacology 20120801

• Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20120801

• Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20120801

• Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.

  Hepatology (Baltimore, Md.) 20120801

• Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• Simultaneous quantitation of HIV-protease inhibitors ritonavir, lopinavir and indinavir in human plasma by UPLC-ESI-MS-MS.

  Journal of chromatographic science 20120801

• Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.

  Virus research 20120801

• Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals.

  AIDS patient care and STDs 20120801

• Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.

  AIDS (London, England) 20120717

• Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

  AIDS (London, England) 20120717

• Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

  The Cochrane database of systematic reviews 20120711

• Nevirapine-based therapy after suppression: can we switch?

  The Lancet. Infectious diseases 20120701

• Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.

  The Lancet. Infectious diseases 20120701

• Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.

  Journal of acquired immune deficiency syndromes (1999) 20120701

• Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.

  European journal of medicinal chemistry 20120701

• Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.

  Antiviral research 20120701

• HIV-2 encephalitis: case report and literature review.

  AIDS patient care and STDs 20120701

• Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.

  The Lancet. Infectious diseases 20120701

• Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

  The New England journal of medicine 20120621

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Protease inhibitor monotherapy: what is its role?

  Current HIV/AIDS reports 20120601

• Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

  The Journal of antimicrobial chemotherapy 20120601

• Trough lopinavir concentrations in preterm HIV-infected infants.

  The Pediatric infectious disease journal 20120601

• Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.

  The Journal of antimicrobial chemotherapy 20120601

• Evaluation of myocardial infarction and coronary artery disease in subjects taking lopinavir/ritonavir: a study using clinical trial and pharmacovigilance databases.

  International journal of clinical pharmacology and therapeutics 20120601

• Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.

  ChemMedChem 20120601

• Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

  PLoS medicine 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

  British journal of clinical pharmacology 20120501

• Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

  Scandinavian journal of infectious diseases 20120501

• HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.

  The Journal of antimicrobial chemotherapy 20120501

• Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

  AIDS patient care and STDs 20120501

• Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.

  Clinical pharmacology and therapeutics 20120501

• Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.

  IUBMB life 20120501

• Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.

  Biopharmaceutics & drug disposition 20120501

• HIV: a growing concern in the elderly population.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120501

• Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

  AIDS (London, England) 20120424

• Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.

  AIDS research and human retroviruses 20120401

• Association of nephrotic syndrome with immune reconstitution inflammatory syndrome.

  Pediatric nephrology (Berlin, Germany) 20120401

• Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

  The Journal of antimicrobial chemotherapy 20120401

• The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.

  The Journal of antimicrobial chemotherapy 20120401

• Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401

• HIV exposure through contact with body fluids.

  Prescrire international 20120401

• Simultaneous quantification of lopinavir and ritonavir in human plasma by high performance liquid chromatography coupled with UV detection.

  Science China. Life sciences 20120401

• Nanotechnology and the treatment of HIV infection.

  Viruses 20120401

• Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.

  Journal of natural products 20120323

• Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20120322

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.

  Molecules (Basel, Switzerland) 20120315

• Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.

  AIDS (London, England) 20120313

• Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

  The Journal of antimicrobial chemotherapy 20120301

• Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

  Current HIV research 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• Transplacental passage of nevirapine, nelfinavir and lopinavir.

  The Netherlands journal of medicine 20120301

• Perinatal lopinavir + ritonavir: adrenal insufficiency.

  Prescrire international 20120301

• Rational approaches to improving selectivity in drug design.

  Journal of medicinal chemistry 20120223

• Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

  AIDS (London, England) 20120220

• Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.

  AIDS (London, England) 20120220

• Diagnosing and responding to violations in the positivity assumption.

  Statistical methods in medical research 20120201

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.

  Journal of acquired immune deficiency syndromes (1999) 20120201

• Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.

  The Journal of antimicrobial chemotherapy 20120201

• Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing.

  Clinical pharmacology and therapeutics 20120201

• Incurred sample reanalysis comparison of dried blood spots and plasma samples on the measurement of lopinavir in clinical samples.

  Bioanalysis 20120201

• HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.

  Memorias do Instituto Oswaldo Cruz 20120201

• A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120115

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20120101

• Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.

  The Lancet. Infectious diseases 20120101

• Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily.

  Journal of acquired immune deficiency syndromes (1999) 20120101

• Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120101

• Mechanisms of alcohol-induced endoplasmic reticulum stress and organ injuries.

  Biochemistry research international 20120101

• The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.

  The Journal of infectious diseases 20120101

• Recent HIV-1 infection: to treat or not to treat, that is the question.

  The Journal of infectious diseases 20120101

• First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.

  The American journal of tropical medicine and hygiene 20120101

• Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

  PloS one 20120101

• Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.

  Antiviral therapy 20120101

• Special aspects of the treatment of HIV-2-infected patients.

  Intervirology 20120101

• Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.

  Antiviral therapy 20120101

• Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.

  Antiviral therapy 20120101

• Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.

  Antiviral therapy 20120101

• The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.

  Antiviral therapy 20120101

• Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

  BMC infectious diseases 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.

  PloS one 20120101

• Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure.

  AIDS research and therapy 20120101

• The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.

  PloS one 20120101

• Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.

  PloS one 20120101

• Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.

  Retrovirology 20120101

• Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.

  Antiviral therapy 20120101

• Palatal Actinomycosis and Kaposi Sarcoma in an HIV-Infected Subject with Disseminated Mycobacterium avium-intracellulare Infection.

  Case reports in medicine 20120101

• HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

  PloS one 20120101

• Novel therapeutic strategies targeting HIV integrase.

  BMC medicine 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.

  PloS one 20120101

• Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

  AIDS research and treatment 20120101

• Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes.

  PloS one 20120101

• Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.

  Journal of medical economics 20120101

• Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.

  PloS one 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.

  AIDS research and treatment 20120101

• Measuring the efficacy of antiretroviral therapy.

  International journal of trichology 20120101

• Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

  PloS one 20120101

• Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.

  PloS one 20120101

• Malaria and hiv in adults: when the parasite runs into the virus.

  Mediterranean journal of hematology and infectious diseases 20120101

• Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.

  BMC pediatrics 20120101

• A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

  HIV clinical trials 20120101

• Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.

  Antiviral therapy 20120101

• Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.

  Journal of clinical pharmacology 20111201

• Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.

  Alcoholism, clinical and experimental research 20111201

• Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children.

  Journal of acquired immune deficiency syndromes (1999) 20111201

• Synthesis and antimycobacterial activity of novel amino alcohols containing central core of the anti-HIV drugs lopinavir and ritonavir.

  Chemical biology & drug design 20111201

• Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

  Journal of pharmacokinetics and pharmacodynamics 20111201

• Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition.

  Pharmacogenetics and genomics 20111201

• HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin.

  Expert review of anti-infective therapy 20111201

• Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20111201

• Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

  The Indian journal of medical research 20111201

• Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.

  AIDS (London, England) 20111128

• Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient.

  AIDS (London, England) 20111128

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

  Journal of clinical pharmacology 20111101

• Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.

  AIDS research and human retroviruses 20111101

• Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20111101

• Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.

  AIDS care 20111101

• Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.

  The Pediatric infectious disease journal 20111101

• Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.

  Antiviral research 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

  Clinical pharmacokinetics 20111101

• Synthesis and antimalarial activity of thioetherhydroxyethylsulfonamides, potential aspartyl protease inhibitors, Part 3.

  European journal of medicinal chemistry 20111101

• P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.

  Journal of medicinal chemistry 20111027

• Resolution of discordant HIV-1 protease resistance rankings using molecular dynamics simulations.

  Journal of chemical information and modeling 20111024

• Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.

  AIDS research and human retroviruses 20111001

• Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20111001

• Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?

  Journal of medical virology 20111001

• HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.

  The Lancet. Infectious diseases 20111001

• Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.

  Therapeutic drug monitoring 20111001

• Once-daily antiretroviral therapy among treatment-experienced Muslim patients fasting for the month of Ramadan.

  Tropical doctor 20111001

• Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.

  The Pediatric infectious disease journal 20111001

• Lopinavir + ritonavir oral solution: dangerous form for newborns.

  Prescrire international 20111001

• Deep molecular characterization of HIV-1 dynamics under suppressive HAART.

  PLoS pathogens 20111001

• Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.

  AIDS research and human retroviruses 20110901

• A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States.

  AIDS care 20110901

• Protease inhibitor monotherapy and the CNS: peace of mind?

  The Journal of antimicrobial chemotherapy 20110901

• Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach.

  European journal of medicinal chemistry 20110901

• Bosentan and oral anticoagulants in HIV patients: what we can learn of cases reported so far.

  Hematology reports 20110831

• Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.

  AIDS (London, England) 20110824

• Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.

  AIDS (London, England) 20110824

• Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.

  British journal of cancer 20110809

• Genetic diversity of HIV type 1 in Montenegro.

  AIDS research and human retroviruses 20110801

• Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

  The Pediatric infectious disease journal 20110801

• Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions.

  Antiviral research 20110801

• The progress made in determining the Mycobacterium tuberculosis structural proteome.

  Proteomics 20110801

• Efficacy of lopinavir-ritonavir reduced dose in HIV-infected patients.

  AIDS patient care and STDs 20110801

• CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.

  Therapeutic drug monitoring 20110801

• UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

• Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

  JAMA 20110706

• Coadministration with lopinavir and ritonavir decreases exposure to BILR 355, a nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.

  Journal of clinical pharmacology 20110701

• [Simplification to lopinavir/ritonavir monotherapy in HIV-infected children].

  Anales de pediatria (Barcelona, Spain : 2003) 20110701

• Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database.

  Journal of acquired immune deficiency syndromes (1999) 20110701

• Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

  AIDS (London, England) 20110619

• Beneficial effects of a switch to a Lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression.

  AIDS research and human retroviruses 20110601

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.

  Journal of pharmaceutical sciences 20110601

• Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

  Therapeutic drug monitoring 20110601

• Lopinavir/ritonavir population pharmacokinetics in neonates and infants.

  British journal of clinical pharmacology 20110601

• Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease.

  Acta crystallographica. Section D, Biological crystallography 20110601

• Darunavir: an effective protease inhibitor for HIV-infected patients.

  Expert review of anti-infective therapy 20110601

• [Exogenous Cushing's syndrome as a serious side-effect of therapy with ritonavir an inhaled fluticasone].

  Klinicka mikrobiologie a infekcni lekarstvi 20110601

• The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts.

  Biochemistry 20110531

• Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization.

  Journal of pharmaceutical and biomedical analysis 20110515

• Risk of triple-class virological failure in children with HIV: a retrospective cohort study.

  Lancet (London, England) 20110507

• A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.

  HIV medicine 20110501

• Lipid and lipoprotein profile in HIV-infected patients treated with lopinavir/ritonavir as a component of the first combination antiretroviral therapy.

  AIDS research and human retroviruses 20110501

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope.

  PLoS pathogens 20110501

• Combination antiretroviral therapy as treatment for human immunodeficiency virus-associated mucosa-associated lymphoid tissue type lymphoma of the nasopharynx.

  Internal medicine journal 20110501

• Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.

  Bioorganic & medicinal chemistry letters 20110415

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas.

  Journal of neuro-oncology 20110401

• Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.

  Scandinavian journal of infectious diseases 20110401

• Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting.

  Journal of acquired immune deficiency syndromes (1999) 20110401

• [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].

  Enfermedades infecciosas y microbiologia clinica 20110401

• Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

  Clinical pharmacokinetics 20110401

• The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.

  Therapeutic drug monitoring 20110401

• Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.

  British journal of clinical pharmacology 20110401

• Trial in youngest group points to HIV treatment overhaul.

  Nature medicine 20110401

• First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data.

  Prescrire international 20110401

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy.

  AIDS (London, England) 20110313

• Total and unbound lopinavir concentrations in the female genital tract of HIV-1 infected women during pregnancy.

  AIDS (London, England) 20110313

• The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium.

  HIV medicine 20110301

• Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene.

  HIV medicine 20110301

• Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.

  HIV medicine 20110301

• Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.

  HIV medicine 20110301

• Microsphere preparation using the untoxic solvent glycofurol.

  Pharmaceutical research 20110301

• Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

  The Journal of antimicrobial chemotherapy 20110301

• Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.

  The Lancet. Infectious diseases 20110301

• First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.

  AIDS (London, England) 20110220

• The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.

  Journal of clinical pharmacology 20110201

• Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.

  Journal of neuro-oncology 20110201

• [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].

  Medecine et maladies infectieuses 20110201

• Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

  European journal of clinical pharmacology 20110201

• Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

  Journal of lipid research 20110201

• Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.

  The Journal of antimicrobial chemotherapy 20110201

• Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.

  Therapeutic drug monitoring 20110201

• Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

  Pharmacotherapy 20110201

• Patent watch: Indian patent office rejects HIV drug formulation patent.

  Nature reviews. Drug discovery 20110201

• From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients.

  Journal of clinical medicine research 20110201

• Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations.

  AIDS (London, England) 20110128

• Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.

  AIDS (London, England) 20110128

• Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial.

  AIDS (London, England) 20110128

• Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

  Journal of medicinal chemistry 20110127

• Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110118

• Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.

  Contemporary clinical trials 20110101

• Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.

  Current HIV research 20110101

• Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats.

  Biological & pharmaceutical bulletin 20110101

• Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.

  Current HIV research 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism.

  PloS one 20110101

• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

  BMC infectious diseases 20110101

• Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.

  Journal of medical economics 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.

  Antiviral therapy 20110101

• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  AIDS research and therapy 20110101

• Antiretroviral therapy-associated acute motor and sensory axonal neuropathy.

  Case reports in neurology 20110101

• HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.

  Lipids in health and disease 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Timely HAART initiation may pave the way for a better viral control.

  BMC infectious diseases 20110101

• Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.

  International journal of STD & AIDS 20110101

• Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.

  PloS one 20110101

• Time for gender mainstreaming in editorial policies.

  Journal of the International AIDS Society 20110101

• A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial.

  Trials 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series.

  Radiation oncology (London, England) 20110101

• Highly active antiretroviral therapy: Does it Sound toxic?

  Journal of pharmacy & bioallied sciences 20110101

• High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

  Journal of the International AIDS Society 20110101

• Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.

  The Indian journal of tuberculosis 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

  European journal of medical research 20110101

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

  European journal of medical research 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in Cameroon.

  Virology journal 20110101

• Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.

  PloS one 20110101

• Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy.

  Neuropsychiatric disease and treatment 20110101

• Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.

  Antiviral therapy 20110101

• Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.

  Antiviral therapy 20110101

• Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda.

  PloS one 20110101

• Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.

  AIDS research and therapy 20110101

• Safety and tolerability of antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20110101

• Asking the right questions: developing evidence-based strategies for treating HIV in women and children.

  BMC public health 20110101

• Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study.

  PloS one 20110101

• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

  The open medicinal chemistry journal 20110101

• A synthetic HIV-1 subtype C backbone generates comparable PR and RT resistance profiles to a subtype B backbone in a recombinant virus assay.

  PloS one 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial.

  The open AIDS journal 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Breast Cancer in the Setting of HIV.

  Pathology research international 20110101

• Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101

• Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

  PloS one 20110101

• Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells.

  Antiviral therapy 20110101

• Recent developments in health law. India's evolving patent laws and WTO obligations: the rejection of Abbott Laboratories' application for a new Kaletra patent.

  The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 20110101

• 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008.

  BMC public health 20110101

• Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.

  European journal of medical research 20110101

• An Apple-core Lesion in the Colon: An Infectious Etiology.

  Journal of global infectious diseases 20110101

• Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

  PloS one 20110101

• Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.

  PloS one 20110101

• Atazanavir in children.

  Prescrire international 20110101

• Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

  PloS one 20110101

• Clinical therapeutics in pregnancy.

  Journal of biomedicine & biotechnology 20110101

• Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

  BMC pediatrics 20110101

• An overview of post exposure prophylaxis for HIV in health care personals: Gujarat scenario.

  Indian journal of sexually transmitted diseases and AIDS 20110101

• Induction maintenance concept for HAART as initial treatment in HIV infected infants.

  European journal of medical research 20110101

• Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

  PloS one 20110101

• Long-term outcomes of liver transplant patients with human immunodeficiency virus infection and end-stage-liver-disease: single center experience.

  European journal of medical research 20110101

• The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.

  Antiviral therapy 20110101

• Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.

  Antiviral therapy 20110101

• [Evidence-based therapeutic drug monitoring of lopinavir].

  Therapie 20110101

• Pregnancy and virologic response to antiretroviral therapy in South Africa.

  PloS one 20110101

• Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy.

  BMC complementary and alternative medicine 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

  Retrovirology 20110101

• HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.

  PloS one 20110101

• Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

  PloS one 20110101

• HIV, Hepatitis B, and Hepatitis C in Zambia.

  Journal of global infectious diseases 20110101

• Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

  PloS one 20110101

• Promoting male involvement to improve PMTCT uptake and reduce antenatal HIV infection: a cluster randomized controlled trial protocol.

  BMC public health 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.

  PloS one 20110101

• Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system.

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda.

  Journal of the International AIDS Society 20110101

• Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.

  PloS one 20110101

• CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

  BMJ (Clinical research ed.) 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Undernutrition among HIV-positive children in Dar es Salaam, Tanzania: antiretroviral therapy alone is not enough.

  BMC public health 20110101

• Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Role of raltegravir in the management of HIV-1 infection.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

  PloS one 20110101

• AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

  BMC research notes 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic Studies.

  Scientia pharmaceutica 20110101

• Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.

  Antiviral therapy 20110101

• Frequency of circulating regulatory T cells increases during chronic HIV infection and is largely controlled by highly active antiretroviral therapy.

  PloS one 20110101

• Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.

  BMC infectious diseases 20110101

• A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

  BMC bioinformatics 20110101

• Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease.

  HIV clinical trials 20110101

• Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

  HIV clinical trials 20110101

• Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

  PloS one 20110101

• Nanomedicine as an emerging approach against intracellular pathogens.

  International journal of nanomedicine 20110101

• Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?

  Patient preference and adherence 20110101

• Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

  International journal of nanomedicine 20110101

• Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.

  Malaria research and treatment 20110101

• Ezetimibe--a new approach in hypercholesterolemia management.

  Pharmacological reports : PR 20110101

• [Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20110101

• [Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20110101

• Enhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticles.

  Therapeutic delivery 20110101

• Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells.

  Drug metabolism letters 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

  Journal of acquired immune deficiency syndromes (1999) 20101201

• Premature senescence of vascular cells is induced by HIV protease inhibitors: implication of prelamin A and reversion by statin.

  Arteriosclerosis, thrombosis, and vascular biology 20101201

• Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells.

  Analytical and bioanalytical chemistry 20101201

• Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.

  Antiviral research 20101201

• Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

  Journal of medical virology 20101201

• Does lopinavir/ritonavir alter the primary gingival epithelium?

  Expert review of anti-infective therapy 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes.

  The Indian journal of medical research 20101201

• A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

  The Journal of infectious diseases 20101115

• Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.

  Journal of medicinal chemistry 20101111

• In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.

  Journal of pharmaceutical and biomedical analysis 20101102

• Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.

  HIV medicine 20101101

• Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20101101

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

  The Journal of antimicrobial chemotherapy 20101101

• Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

  The Journal of antimicrobial chemotherapy 20101101

• Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

  AIDS research and human retroviruses 20101101

• Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy.

  Advances in therapy 20101101

• The Mycobacterium tuberculosis drugome and its polypharmacological implications.

  PLoS computational biology 20101101

• Cryo electron tomography of native HIV-1 budding sites.

  PLoS pathogens 20101101

• Structural analysis of HIV-1 maturation using cryo-electron tomography.

  PLoS pathogens 20101101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101101

• Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

  Viruses 20101101

• Molecular Basis for Drug Resistance in HIV-1 Protease.

  Viruses 20101101

• HIV protease inhibitors alter innate immune response signaling to double-stranded RNA in oral epithelial cells: implications for immune reconstitution inflammatory syndrome?

  AIDS (London, England) 20101023

• Antiretroviral therapies in women after single-dose nevirapine exposure.

  The New England journal of medicine 20101014

• Antiretroviral treatment for children with peripartum nevirapine exposure.

  The New England journal of medicine 20101014

• Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.

  HIV medicine 20101001

• Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!

  Transplant international : official journal of the European Society for Organ Transplantation 20101001

• Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

  European journal of clinical pharmacology 20101001

• Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy.

  Diabetes care 20101001

• Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir.

  European journal of clinical pharmacology 20101001

• Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

  The Journal of antimicrobial chemotherapy 20101001

• Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection.

  Drugs 20101001

• Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines.

  Current HIV research 20101001

• Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation.

  AIDS (London, England) 20100924

• Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

  AIDS (London, England) 20100924

• Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy.

  AIDS (London, England) 20100924

• Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

  AIDS (London, England) 20100910

• Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

  JAMA 20100908

• HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.

  Journal of pharmaceutical and biomedical analysis 20100905

• The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy.

  Journal of clinical pharmacology 20100901

• No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial.

  HIV medicine 20100901

• pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.

  The Journal of pharmacology and experimental therapeutics 20100901

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Treatment. Employee's allegations survive test under False Claims Act.

  AIDS policy & law 20100901

• Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy.

  The Pediatric infectious disease journal 20100801

• Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20100801

• Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

  The Journal of pharmacology and experimental therapeutics 20100801

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  The Journal of antimicrobial chemotherapy 20100801

• Lopinavir tablet pharmacokinetics with an increased dose during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.

  Pharmacotherapy 20100801

• Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20100801

• Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.

  AIDS research and human retroviruses 20100801

• Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.

  Toxins 20100801

• Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

  Archives of internal medicine 20100726

• Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.

  AIDS (London, England) 20100717

• Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

  Antimicrobial agents and chemotherapy 20100701

• Syndrome of inappropriate antidiuretic hormone associated with lopinavir therapy.

  The Pediatric infectious disease journal 20100701

• Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis.

  Liver international : official journal of the International Association for the Study of the Liver 20100701

• Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

  The Journal of antimicrobial chemotherapy 20100701

• Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

  British journal of pharmacology 20100701

• Role of Gag in HIV Resistance to Protease Inhibitors.

  Viruses 20100701

• Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation.

  AIDS (London, England) 20100619

• Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.

  Journal of acquired immune deficiency syndromes (1999) 20100601

• Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir.

  The Analyst 20100601

• Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601

• Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.

  AIDS care 20100601

• Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care.

  Medical care 20100601

• Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.

  Archives of disease in childhood 20100601

• Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.

  AIDS research and human retroviruses 20100601

• Once-daily dosing of lopinavir/ritonavir (Kaletra) receives FDA approval.

  AIDS patient care and STDs 20100601

• Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction.

  International journal of emergency medicine 20100601

• FDA notifications. FDA approves new dosing for Kaletra.

  AIDS alert 20100601

• Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases.

  Journal of chemical information and modeling 20100524

• Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.

  AIDS (London, England) 20100515

• Cerebrospinal fluid HIV-1 virological escape with lymphocytic meningitis under lopinavir/ritonavir monotherapy.

  AIDS (London, England) 20100515

• HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

  Biochimica et biophysica acta 20100501

• Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

  The Journal of antimicrobial chemotherapy 20100501

• Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

  Journal of virology 20100501

• Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.

  The Journal of antimicrobial chemotherapy 20100501

• Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.

  AIDS research and human retroviruses 20100501

• Special issue: retroviral enzymes.

  Viruses 20100501

• Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.

  The Journal of infectious diseases 20100415

• Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids.

  Molecular pharmaceutics 20100405

• Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20100401

• High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients.

  European journal of clinical pharmacology 20100401

• Lopinavir protein binding in HIV-1-infected pregnant women.

  HIV medicine 20100401

• Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

  The Journal of antimicrobial chemotherapy 20100401

• Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).

  Journal of clinical pharmacology 20100401

• ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.

  Pharmacogenetics and genomics 20100401

• Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100401

• The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.

  AIDS (London, England) 20100313

• Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.

  Journal of acquired immune deficiency syndromes (1999) 20100301

• Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.

  The Journal of antimicrobial chemotherapy 20100301

• Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

  Xenobiotica; the fate of foreign compounds in biological systems 20100301

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

  PLoS neglected tropical diseases 20100301

• FDA notifications. Kaletra revisions to packaging approved.

  AIDS alert 20100301

• Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model.

  Journal of pharmaceutical sciences 20100201

• Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

  HIV medicine 20100201

• Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).

  Journal of pharmaceutical sciences 20100201

• Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.

  Journal of pharmaceutical sciences 20100201

• Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).

  Antiviral research 20100201

• Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.

  Antimicrobial agents and chemotherapy 20100201

• HIV protease inhibitors block oral epithelial cell DNA synthesis.

  Archives of oral biology 20100201

• HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

  Pharmacogenetics and genomics 20100201

• [LC-MS/MS method for simultaneous quantification of lopinavir and ritonavir in human plasma].

  Yao xue xue bao = Acta pharmaceutica Sinica 20100201

• Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

  Lancet (London, England) 20100130

• HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

  Journal of medicinal chemistry 20100128

• The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteers.

  AIDS (London, England) 20100116

• Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

  Archives of internal medicine 20100111

• DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.

  Archives of internal medicine 20100111

• HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.

  Gastroenterology 20100101

• Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxis.

  The Journal of infection 20100101

• Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets.

  The Pediatric infectious disease journal 20100101

• Factors influencing lopinavir and atazanavir plasma concentration.

  The Journal of antimicrobial chemotherapy 20100101

• Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial.

  The Journal of antimicrobial chemotherapy 20100101

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• Pharmacogenomic adaptation of antiretroviral therapy: overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism.

  European journal of clinical pharmacology 20100101

• Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

  Clinical pharmacokinetics 20100101

• The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

  British journal of pharmacology 20100101

• The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.

  British journal of clinical pharmacology 20100101

• Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.

  BMC gastroenterology 20100101

• Predicting Bevirimat resistance of HIV-1 from genotype.

  BMC bioinformatics 20100101

• Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages.

  PloS one 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.

  PloS one 20100101

• Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

  PloS one 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.

  Antiviral therapy 20100101

• Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

  PloS one 20100101

• 'I will not let my HIV status stand in the way.' Decisions on motherhood among women on ART in a slum in Kenya- a qualitative study.

  BMC women's health 20100101

• A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study.

  Analytical chemistry insights 20100101

• Semen may harbor HIV despite effective HAART: another piece in the puzzle.

  PloS one 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• HIV protease inhibitors activate the adipocyte renin angiotensin system.

  Antiviral therapy 20100101

• Dynamics of lamin-A processing following precursor accumulation.

  PloS one 20100101

• Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

  PloS one 20100101

• An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.

  PloS one 20100101

• A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008.

  PloS one 20100101

• Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

  AIDS research and therapy 20100101

• Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.

  PloS one 20100101

• Making it happen, level 2.

  Global health action 20100101

• Development of a liposomal nanodelivery system for nevirapine.

  Journal of biomedical science 20100101

• Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

  PloS one 20100101

• Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study.

  AIDS research and therapy 20100101

• Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time.

  PloS one 20100101

• High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.

  Biological & pharmaceutical bulletin 20100101

• Diagnosis of systemic toxoplasmosis with HIV infection using DNA extracted from paraffin-embedded tissue for polymerase chain reaction: a case report.

  Journal of medical case reports 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101

• Boosted protease inhibitor monotherapy. What have we learnt after seven years of research?

  AIDS reviews 20100101

• Anti-retroviral therapy-induced status epilepticus in 'pseudo-HIV serodeconversion'.

  General hospital psychiatry 20100101

• Getting the balance right: Established and emerging therapies for major depressive disorders.

  Neuropsychiatric disease and treatment 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Human immunodeficiency virus and leishmaniasis.

  Journal of global infectious diseases 20100101

• Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

  Retrovirology 20100101

• Prevention of post-operative infections after surgical treatment of bite wounds.

  GMS Krankenhaushygiene interdisziplinar 20100101

• Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia.

  PloS one 20100101

• Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease.

  Retrovirology 20100101

• Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

  European journal of medical research 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

  Antiviral therapy 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.

  PloS one 20100101

• Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.

  Antiviral therapy 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

  PharmacoEconomics 20100101

• Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

  PharmacoEconomics 20100101

• Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

  BMC infectious diseases 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virus.

  Case reports in dermatology 20100101

• Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

  Infection and drug resistance 20100101

• An application of collaborative targeted maximum likelihood estimation in causal inference and genomics.

  The international journal of biostatistics 20100101

• Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

  Indian journal of sexually transmitted diseases and AIDS 20100101

• Pharmacogenetics in the brazilian population.

  Frontiers in pharmacology 20100101

• Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

  HIV/AIDS (Auckland, N.Z.) 20100101

• HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• New and emerging agents in the management of lipodystrophy in HIV-infected patients.

  HIV/AIDS (Auckland, N.Z.) 20100101

• HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy.

  Movement disorders : official journal of the Movement Disorder Society 20091215

• Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20091210

• Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

  Journal of medicinal chemistry 20091210

• [Raised tattoos in a human-immunodeficiency-virus-infected patient].

  Enfermedades infecciosas y microbiologia clinica 20091201

• Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine.

  Pharmacy world & science : PWS 20091201

• Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.

  The Pediatric infectious disease journal 20091201

• Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.

  Therapeutic drug monitoring 20091201

• Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.

  The Annals of pharmacotherapy 20091201

• Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir.

  The Annals of pharmacotherapy 20091201

• The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.

  Expert review of anti-infective therapy 20091201

• HIV-1 Protease: Structural Perspectives on Drug Resistance.

  Viruses 20091201

• Current and Novel Inhibitors of HIV Protease.

  Viruses 20091201

• How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials.

  AIDS (London, England) 20091113

• Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

  HIV medicine 20091101

• Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage.

  The Journal of antimicrobial chemotherapy 20091101

• [Regimen simplification: lopinavir/ritonavir with or without efavirenz].

  Enfermedades infecciosas y microbiologia clinica 20091101

• Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.

  The Journal of antimicrobial chemotherapy 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091101

• Modified directly observed therapy to improve HIV treatment outcomes: little impact with potent, once-daily therapy in unselected antiretroviral-naïve patients.

  Current HIV/AIDS reports 20091101

• Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

  Current HIV research 20091101

• Antiretroviral compounds and cholesterol efflux from macrophages.

  Atherosclerosis 20091001

• Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

  The Journal of antimicrobial chemotherapy 20091001

• Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20091001

• A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

• Enfuvirtide: a safe and effective antiretroviral agent for human immunodeficiency virus-infected patients shortly after liver transplantation.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20091001

• Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.

  Pharmacogenomics 20091001

• Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.

  PLoS medicine 20091001

• Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid/liquid extraction, and ultrafast LC-MS/MS.

  Analytica chimica acta 20090928

• Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090915

• Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

  Bioorganic & medicinal chemistry letters 20090915

• Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

  AIDS (London, England) 20090910

• Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2.

  European journal of medicinal chemistry 20090901

• The role of transporters in the pharmacokinetics of orally administered drugs.

  Pharmaceutical research 20090901

• Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.

  The Journal of infectious diseases 20090901

• Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection.

  Sexual health 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.

  Expert review of anti-infective therapy 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.

  AIDS (London, England) 20090824

• Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

  Journal of acquired immune deficiency syndromes (1999) 20090815

• Lopinavir co-induces insulin resistance and ER stress in human adipocytes.

  Biochemical and biophysical research communications 20090814

• Lopinavir/ritonavir in pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin.

  Drug metabolism and disposition: the biological fate of chemicals 20090801

• Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

  Clinical pharmacology and therapeutics 20090801

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20090801

• Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

  AIDS (London, England) 20090731

• First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.

  AIDS (London, England) 20090717

• Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

  AIDS (London, England) 20090717

• Modified directly observed antiretroviral therapy compared with self-administered therapy in treatment-naive HIV-1-infected patients: a randomized trial.

  Archives of internal medicine 20090713

• Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.

  Journal of medicinal chemistry 20090709

• Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

  Antimicrobial agents and chemotherapy 20090701

• Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

  Journal of clinical microbiology 20090701

• HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.

  Biochemical pharmacology 20090701

• Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes.

  AIDS patient care and STDs 20090701

• Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.

  Journal of chemical information and modeling 20090701

• Effectiveness of commercial inhibitors against subtype F HIV-1 protease.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

  The Journal of antimicrobial chemotherapy 20090601

• Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

  The Journal of antimicrobial chemotherapy 20090601

• Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.

  AIDS (London, England) 20090601

• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

  Journal of acquired immune deficiency syndromes (1999) 20090601

• Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment.

  The Journal of antimicrobial chemotherapy 20090601

• Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

  AIDS (London, England) 20090601

• Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.

  Prescrire international 20090601

• Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?

  Journal of infection in developing countries 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• Does HIV-1 subtype D have a higher risk of vertical transmission than other HIV subtypes?

  The Journal of infectious diseases 20090515

• Water-soluble prodrugs of the human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

  Journal of medicinal chemistry 20090514

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

  Journal of computer-aided molecular design 20090501

• Application of a rapid and selective method for the simultaneous determination of protease inhibitors, lopinavir and ritonavir in human plasma by UPLC-ESI-MS/MS for bioequivalence study in Indian subjects.

  Journal of pharmaceutical and biomedical analysis 20090501

• Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

  The Journal of antimicrobial chemotherapy 20090501

• Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• New cardiac warnings for Kaletra.

  AIDS patient care and STDs 20090501

• FDA notifications. Generic lopinavir/ritonavir approved by FDA.

  AIDS alert 20090501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090501

• [Medication change due to side effects or possible long-term complications. Side effect management with vision].

  MMW Fortschritte der Medizin 20090430

• Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

  AIDS (London, England) 20090427

• 2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

  Journal of medicinal chemistry 20090423

• The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.

  Journal of acquired immune deficiency syndromes (1999) 20090415

• A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks.

  Journal of acquired immune deficiency syndromes (1999) 20090415

• Salting-out assisted liquid/liquid extraction with acetonitrile: a new high throughput sample preparation technique for good laboratory practice bioanalysis using liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20090401

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.

  American journal of physiology. Endocrinology and metabolism 20090401

• Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.

  Journal of acquired immune deficiency syndromes (1999) 20090401

• FDA approves three generics.

  AIDS patient care and STDs 20090401

• Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

  PLoS pathogens 20090401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090401

• Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.

  Journal watch. AIDS clinical care 20090401

• Differences in lopinavir plasma concentrations comparing Kaletra film coated tablets and soft gelatine capsules that result in various lipid abnormalities.

  Drug metabolism letters 20090401

• Synthesis and antimalarial activity of hydroxyethylpiperazine derivatives.

  European journal of medicinal chemistry 20090301

• GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

  Antimicrobial agents and chemotherapy 20090301

• Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

  Antimicrobial agents and chemotherapy 20090301

• Study of the gastrointestinal tolerance of a new tablet formulation of the lopinavir/ritonavir antiretroviral in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.

  The Pediatric infectious disease journal 20090301

• Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.

  The American journal of pathology 20090301

• A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090301

• Timing the emergence of resistance to anti-HIV drugs with large genetic barriers.

  PLoS computational biology 20090301

• Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.

  AIDS research and human retroviruses 20090301

• Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.

  PLoS pathogens 20090301

• Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.

  Project Inform perspective 20090301

• Prezista fares better than Kaletra in first line therapy.

  Project Inform perspective 20090301

• Protease inhibitor levels in hair strongly predict virologic response to treatment.

  AIDS (London, England) 20090220

• Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

  The Pediatric infectious disease journal 20090201

• Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start?

  Current HIV/AIDS reports 20090201

• Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.

  Journal of clinical pharmacology 20090201

• Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).

  HIV medicine 20090201

• ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.

  Pharmacogenomics 20090201

• Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.

  Advances in therapy 20090201

• Non-occupational postexposure prophylaxis for HIV: a systematic review.

  Health technology assessment (Winchester, England) 20090201

• [Atazanavir-induced nephrolithiasis].

  Enfermedades infecciosas y microbiologia clinica 20090201

• HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

  AIDS (London, England) 20090128

• Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection.

  Statistics in medicine 20090115

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites.

  The Journal of infectious diseases 20090101

• Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda.

  BMJ (Clinical research ed.) 20090101

• Comparison of Markov model and discrete-event simulation techniques for HIV.

  PharmacoEconomics 20090101

• Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

  Antiviral therapy 20090101

• Darunavir: a review of its use in the management of HIV infection in adults.

  Drugs 20090101

• HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

  PloS one 20090101

• Is PPARγ a prospective player in HIV-1-associated bone disease?

  PPAR research 20090101

• Seven-year follow-up on lopinavir/ ritonavir monotherapy.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

  Antiviral therapy 20090101

• Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

  Antiviral therapy 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.

  Antiviral therapy 20090101

• Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

  PloS one 20090101

• Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies.

  HIV clinical trials 20090101

• Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.

  HIV clinical trials 20090101

• Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

  BMC infectious diseases 20090101

• Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube.

  Internal medicine (Tokyo, Japan) 20090101

• Bioequivalence study of two fixed dose combination tablet formulations of lopinavir and ritonavir in healthy volunteers.

  Arzneimittel-Forschung 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

  Journal of the International AIDS Society 20090101

• Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.

  Antiviral therapy 20090101

• Novel methodology for antiretroviral quantitation in the female genital tract.

  HIV clinical trials 20090101

• The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.

  Interdisciplinary perspectives on infectious diseases 20090101

• Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.

  Vascular health and risk management 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.

  BMC infectious diseases 20090101

• Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.

  BMC bioinformatics 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.

  Antiviral therapy 20090101

• Understanding the pharmacokinetics of Coartem.

  Malaria journal 20090101

• Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.

  BMC infectious diseases 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

  HIV clinical trials 20090101

• A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.

  Antiviral therapy 20090101

• Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.

  Antiviral therapy 20090101

• Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging.

  PloS one 20090101

• First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better.

  AIDS reviews 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model.

  Obstetrics and gynecology international 20090101

• Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.

  BMC infectious diseases 20090101

• Hepatic profile analyses of tipranavir in Phase II and III clinical trials.

  BMC infectious diseases 20090101

• Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study.

  Journal of the International AIDS Society 20090101

• Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

  AIDS research and therapy 20090101

• Progressive Multifocal Leukoencephalopathy in HIV-Infected Children: A Case Report and Literature Review.

  International journal of pediatrics 20090101

• Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20090101

• Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study).

  HIV clinical trials 20090101

• Fatal dual infection with Salmonella and Mycobacterium avium complex infection in a patient with advanced acquired immunodeficiency syndrome: a case report.

  Cases journal 20090101

• Raltegravir: The evidence of its therapeutic value in HIV-1 infection.

  Core evidence 20090101

• Profile of darunavir in the management of treatment-experienced HIV patients.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance.

  Journal of pharmaceutical and biomedical analysis 20081215

• Lopinavir exposure with an increased dose during pregnancy.

  Journal of acquired immune deficiency syndromes (1999) 20081215

• Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081215

• Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial.

  Journal of acquired immune deficiency syndromes (1999) 20081215

• Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.

  Clinical pharmacology and therapeutics 20081201

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• Improved tolerability and quality of life with the new lopinavir/ritonavir tablet formulation.

  The Journal of infection 20081201

• HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?

  Sexually transmitted diseases 20081201

• [A case of acquired encephalopathy in a child. A cause that we thought had disappeared].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20081201

• [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• More Kaletra monotherapy results.

  Project Inform perspective 20081201

• Civil society strategy for the compulsory licensing of lopinavir/ritonavir: the Brazilian case.

  HIV/AIDS policy & law review 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• [Lopinavir/ritonavir monotherapy in the treatment of HIV infection. Introduction].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Monotherapy in treatment-naïve patients].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [The 'induction-maintenance' strategy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy. Possible indications].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy as a simplification strategy in antiretroviral therapy in clinical practice].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Prognostic factors of virological response in patients treated with lopinavir/ritonavir monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Lopinavir/ritonavir monotherapy for the treatment of HIV-1 infection: the emergence of resistance].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Penetration in reservoirs].

  Enfermedades infecciosas y microbiologia clinica 20081201

• [Pharmacoeconomic aspects of lopinavir/ritonavir monotherapy].

  Enfermedades infecciosas y microbiologia clinica 20081201

• Early antiretroviral therapy and mortality among HIV-infected infants.

  The New England journal of medicine 20081120

• Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20081115

• Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

  AIDS (London, England) 20081112

• Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir.

  AIDS (London, England) 20081112

• Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors.

  The Journal of antimicrobial chemotherapy 20081101

• Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.

  Journal of medical virology 20081101

• Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

  The Pediatric infectious disease journal 20081101

• Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20081101

• Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.

  British journal of pharmacology 20081101

• 96-week CASTLE data show similar efficacy results.

  AIDS patient care and STDs 20081101

• [A case of acute renal failure involving high amounts of tenofovir after HAART start].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20081101

• Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors.

  Journal of theoretical biology 20081021

• Lopinavir impairs protein synthesis and induces eEF2 phosphorylation via the activation of AMP-activated protein kinase.

  Journal of cellular biochemistry 20081015

• Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

  The Journal of antimicrobial chemotherapy 20081001

• Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

  Therapeutic drug monitoring 20081001

• Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications.

  Therapeutic drug monitoring 20081001

• The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

  AIDS (London, England) 20081001

• [Chemical characteristics, mechanism of action and antiviral activity of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir in treatment-naïve patients. The ARTEMIS study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Darunavir as first-line therapy. The TITAN study].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Safety and tolerability of darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• [Resistance to darunavir].

  Enfermedades infecciosas y microbiologia clinica 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• Pharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended release.

  Therapeutics and clinical risk management 20081001

• HIV-protease inhibitors block the enzymatic activity of purified Ste24p.

  Biochemical and biophysical research communications 20080919

• Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.

  Virology 20080915

• Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir.

  Protein science : a publication of the Protein Society 20080901

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

  Expert opinion on pharmacotherapy 20080901

• Women and non-whites new to HAART respond similarly to men and whites.

  AIDS patient care and STDs 20080901

• CASTLE data show no gender differences.

  AIDS patient care and STDs 20080901

• Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.

  Current HIV research 20080901

• Initial treatment of HIV-1 infection.

  The New England journal of medicine 20080828

• Initial treatment of HIV-1 infection.

  The New England journal of medicine 20080828

• A king in the CASTLE? Optimum initial HIV protease inhibitor.

  Lancet (London, England) 20080823

• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

  Lancet (London, England) 20080823

• Noninferiority and lopinavir/ritonavir monotherapy trials.

  AIDS (London, England) 20080820

• No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080815

• Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

  Journal of acquired immune deficiency syndromes (1999) 20080815

• Metabolic changes in protease inhibitor-naive patients treated for 1 year with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20080815

• Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

  Journal of medicinal chemistry 20080814

• Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

  Journal of the American College of Cardiology 20080812

• CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.

  Clinical pharmacology and therapeutics 20080801

• CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

  European journal of clinical pharmacology 20080801

• Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

  Therapeutic drug monitoring 20080801

• Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.

  International journal of STD & AIDS 20080801

• Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.

  International journal of STD & AIDS 20080801

• FDA notifications. Lopinavir/ritonavir label updated.

  AIDS alert 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

  AIDS (London, England) 20080731

• Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data.

  Journal of pharmaceutical and biomedical analysis 20080715

• A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

  The Journal of infectious diseases 20080715

• Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.

  International journal of pharmaceutics 20080709

• Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.

  Clinical pharmacology and therapeutics 20080701

• HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

• A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.

  Journal of virological methods 20080701

• Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.

  The Pediatric infectious disease journal 20080701

• Possible antiretroviral therapy-warfarin drug interaction.

  Pharmacotherapy 20080701

• Induction effects of ritonavir: implications for drug interactions.

  The Annals of pharmacotherapy 20080701

• Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.

  PLoS medicine 20080701

• New pediatric dosing information for Kaletra.

  AIDS patient care and STDs 20080701

• Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications.

  AIDS (London, England) 20080619

• Acute meningoencephalitis in chronic HIV infection: clinical resolution with lopinavir-ritonavir-containing therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080615

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

  The Journal of antimicrobial chemotherapy 20080601

• Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

  The Journal of antimicrobial chemotherapy 20080601

• First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.

  The Journal of antimicrobial chemotherapy 20080601

• Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

  Therapeutic drug monitoring 20080601

• Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.

  Current HIV research 20080601

• Stability of antiretroviral regimens in patients with viral suppression.

  AIDS (London, England) 20080531

• Safety of long-term lopinavir plasma-levels in patients with liver disease.

  European journal of medical research 20080526

• Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry.

  Analytical chemistry 20080515

• Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515

• Class-sparing regimens for initial treatment of HIV-1 infection.

  The New England journal of medicine 20080515

• Initial treatment for HIV infection--an embarrassment of riches.

  The New England journal of medicine 20080515

• High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.

  AIDS (London, England) 20080511

• Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.

  The Journal of antimicrobial chemotherapy 20080501

• Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.

  HIV medicine 20080501

• Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

  The Pediatric infectious disease journal 20080501

• Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.

  Journal of clinical pharmacology 20080501

• Undetectable HIV-1 viral load in the fluid of bullous skin lesion in a patient receiving highly active antiretroviral therapy.

  International journal of STD & AIDS 20080501

• Kaletra lower-strength pediatric tablet approved in Europe.

  AIDS patient care and STDs 20080501

• Inhibitory quotient in HIV pharmacology.

  Current opinion in HIV and AIDS 20080501

• Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.

  Current opinion in HIV and AIDS 20080501

• [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].

  MMW Fortschritte der Medizin 20080428

• Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.

  Journal of computational chemistry 20080415

• Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20080415

• Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.

  Journal of acquired immune deficiency syndromes (1999) 20080415

• A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.

  The Journal of biological chemistry 20080411

• Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.

  Clinical pharmacology and therapeutics 20080401

• Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

  Antimicrobial agents and chemotherapy 20080401

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.

  Pediatrics 20080401

• Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.

  HIV medicine 20080401

• A bioequivalence study comparing two formulations of lopinavir/ritonavir capsules.

  International journal of clinical pharmacology and therapeutics 20080401

• An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.

  AIDS patient care and STDs 20080401

• Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir/ritonavir poisoning in a HIV-positive patient.

  AIDS (London, England) 20080330

• Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

  HIV medicine 20080301

• Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080301

• CASTLE study showed similar efficacy.

  AIDS patient care and STDs 20080301

• [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].

  Enfermedades infecciosas y microbiologia clinica 20080301

• Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-Infected individuals in Brazil.

  Journal of acquired immune deficiency syndromes (1999) 20080301

• Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.

  TreatmentUpdate 20080301

• Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.

  TreatmentUpdate 20080301

• The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

  Clinical pharmacology and therapeutics 20080201

• Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20080201

• Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

  Antimicrobial agents and chemotherapy 20080201

• Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.

  HIV medicine 20080201

• [Thromboembolic events at the time of highly active antiretroviral therapies against human immunodeficiency virus].

  La Revue de medecine interne 20080201

• Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.

  Current medical research and opinion 20080201

• Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.

  AIDS (London, England) 20080130

• Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

  AIDS (London, England) 20080130

• Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

  AIDS (London, England) 20080111

• Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.

  AIDS (London, England) 20080111

• Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

  AIDS (London, England) 20080111

• Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.

  AIDS (London, England) 20080111

• Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20080101

• Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

  The Journal of antimicrobial chemotherapy 20080101

• Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

  The Journal of antimicrobial chemotherapy 20080101

• Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080101

• Drug interactions between HIV protease inhibitors and acid-reducing agents.

  Clinical pharmacokinetics 20080101

• Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients.

  HIV clinical trials 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.

  Rapid communications in mass spectrometry : RCM 20080101

• Pharmacokinetic parameters of lopinavir determined by moment analysis in Japanese HIV type 1-infected patients.

  AIDS research and human retroviruses 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).

  TreatmentUpdate 20080101

• Anti-HIV agents. A trial of Kaletra monotherapy.

  TreatmentUpdate 20080101

• Anti-HIV agents. Monotherapy studies--points to consider.

  TreatmentUpdate 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Acute renal failure in an AIDS patient on tenofovir: a case report.

  Journal of medical case reports 20080101

• Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

  AIDS reviews 20080101

• Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors.

  Antiviral therapy 20080101

• Proteochemometric modeling of HIV protease susceptibility.

  BMC bioinformatics 20080101

• Ugandan children receive lower-strength Aluvia.

  AIDS patient care and STDs 20080101

• Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.

  HIV clinical trials 20080101

• Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis.

  Journal of postgraduate medicine 20080101

• Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.

  Acta poloniae pharmaceutica 20080101

• Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.

  HIV clinical trials 20080101

• FDA notifications. FDA approves half-strength Kaletra.

  AIDS alert 20080101

• Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis: is co-trimoxazole the culprit?

  Journal of postgraduate medicine 20080101

• Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.

  Antiviral therapy 20080101

• 'White coat compliance' limits the reliability of therapeutic drug monitoring in HIV-1-infected patients.

  HIV clinical trials 20080101

• Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.

  Clinical pharmacokinetics 20080101

• Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

  AIDS research and therapy 20080101

• [Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].

  Enfermedades infecciosas y microbiologia clinica 20080101

• [Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20080101

• Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.

  Pharmacology 20080101

• Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.

  BMC medical research methodology 20080101

• Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

  PloS one 20080101

• Prevention of the sexual transmission of HIV-1: preparing for success.

  Journal of the International AIDS Society 20080101

• Sustained increase of HDL cholesterol over a 72-week period in HIV-infected patients exposed to an antiretroviral regimen including lopinavir/ritonavir.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.

  Retrovirology 20080101

• Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.

  Antiviral therapy 20080101

• Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.

  Antiviral therapy 20080101

• The use of artificial neural networks in prediction of congenital CMV outcome from sequence data.

  Bioinformatics and biology insights 20080101

• Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina.

  Journal of the International AIDS Society 20080101

• Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.

  The Journal of infectious diseases 20071215

• Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20071201

• Uveitis associated with concurrent administration of rifabutin and lopinavir/ritonavir (Kaletra).

  Eye (London, England) 20071201

• Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.

  The Journal of infectious diseases 20071201

• Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

  AIDS patient care and STDs 20071201

• A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.

  AIDS research and human retroviruses 20071201

• Fatal Streptococcus equi subsp. ruminatorum infection in a man.

  Emerging infectious diseases 20071201

• Resistance testing methodologies and mechanisms of resistance.

  Journal of HIV therapy 20071201

• Review of tenofovir-emtricitabine.

  Therapeutics and clinical risk management 20071201

• HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity.

  AIDS (London, England) 20071112

• Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

  Journal of medical virology 20071101

• Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.

  Clinical and vaccine immunology : CVI 20071101

• Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

  The Journal of antimicrobial chemotherapy 20071101

• Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

  Basic & clinical pharmacology & toxicology 20071101

• Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

  HIV medicine 20071101

• Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

  PLoS medicine 20071101

• Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.

  Clinical therapeutics 20071101

• Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.

  AIDS (London, England) 20071018

• Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.

  AIDS (London, England) 20071018

• Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

  The Journal of antimicrobial chemotherapy 20071001

• Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues.

  The Journal of antimicrobial chemotherapy 20071001

• Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

  Therapeutic drug monitoring 20071001

• Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20071001

• Darunavir phase 3 study data released.

  AIDS patient care and STDs 20071001

• FDA notifications. Abbott sends out provider letter about Kaletra for kids.

  AIDS alert 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

  AIDS (London, England) 20070912

• Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

  AIDS (London, England) 20070912

• Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

  Journal of medicinal chemistry 20070906

• Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20070903

• In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

  Antimicrobial agents and chemotherapy 20070901

• Patient preferences among third agent HIV medications: a US and German perspective.

  AIDS care 20070901

• Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.

  Journal of acquired immune deficiency syndromes (1999) 20070901

• [Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20070901

• Children with HIV are not small adults: what is different in pharmacology?

  Current opinion in HIV and AIDS 20070901

• Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Interaction between lopinavir/ritonavir and warfarin.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070814

• Identification and characterization of an aspartyl protease from Cryptococcus neoformans.

  FEBS letters 20070807

• Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.

  Clinical pharmacology and therapeutics 20070801

• Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.

  The Journal of antimicrobial chemotherapy 20070801

• Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.

  Journal of clinical pharmacology 20070801

• Hair loss induced by lopinavir-ritonavir.

  Pharmacotherapy 20070801

• Report from the XVI International HIV Drug Resistance Workshop.

  AIDS clinical care 20070801

• Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.

  Prescrire international 20070801

• Genotype testing and antiretroviral resistance profiles from HIV-1 patients experiencing therapeutic failure in northeast Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20070801

• Aluvia tablet approved in 19 African countries.

  AIDS patient care and STDs 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor.

  International journal of pharmaceutics 20070718

• [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].

  Medicina clinica 20070714

• Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

  Lancet (London, England) 20070707

• Abbott's AIDS fight-back.

  Nature 20070705

• Effects of lopinavir-ritonavir combined therapy during the rat pregnancy. Morphological and biochemical aspects.

  European journal of obstetrics, gynecology, and reproductive biology 20070701

• A novel validated LC method for quantitation of lopinavir in bulk drug and pharmaceutical formulation in the presence of its potential impurities and degradation products.

  Biomedical chromatography : BMC 20070701

• Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.

  The Annals of pharmacotherapy 20070701

• Clinical ritonavir and lopinavir hypersensitivity confirmed by a specific in vitro cellular allergen stimulation test.

  Current HIV research 20070701

• Optimal timing and duration of induction therapy for HIV-1 infection.

  PLoS computational biology 20070701

• Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.

  Journal of drugs in dermatology : JDD 20070701

• Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.

  AIDS (London, England) 20070619

• A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20070601

• HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.

  Biochemical pharmacology 20070601

• Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20070601

• Access to drugs: the case of Abbott in Thailand.

  The Lancet. Infectious diseases 20070601

• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

  Journal of acquired immune deficiency syndromes (1999) 20070601

• Kaletra single agent HAART after intolerance of NRTI- and NNRTI-containing regimens following kidney transplantation.

  Infection 20070601

• Pharmacologic treatment of SARS: current knowledge and recommendations.

  Annals of the Academy of Medicine, Singapore 20070601

• HPV oral infection. Case report of an HIV-positive Nigerian sex worker.

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20070601

• FDA notifications. FDA grants approval for generic didanosine for oral solution.

  AIDS alert 20070601

• Response to 'Nifedipine-lopinavir/ritonavir severe interaction: a case report'.

  AIDS (London, England) 20070531

• Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States.

  The Journal of infectious diseases 20070515

• Steady-state lopinavir levels in third trimester of pregnancy.

  AIDS (London, England) 20070511

• Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.

  The Journal of antimicrobial chemotherapy 20070501

• Structural confirmation of regioisomers of Lopinavir impurities using MS and gradient COSY (1H and 13C NMR assignment of Lopinavir impurities).

  Magnetic resonance in chemistry : MRC 20070501

• Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

  Pediatrics 20070501

• Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20070501

• HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Monotherapy with lopinavir/ritonavir.

  Expert opinion on investigational drugs 20070501

• HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

  PLoS computational biology 20070501

• Abbott agrees to expand access to Kaletra/Aluvia.

  AIDS patient care and STDs 20070501

• Pivotal moments in HIV treatment: the 14th CROI.

  The AIDS reader 20070501

• Combining resistance and pharmacology for optimum patient care.

  Current opinion in HIV and AIDS 20070501

• Improving access to second-line antiretrovirals.

  Lancet (London, England) 20070421

• Drug access. AHF chides Abbott for ban on HIV drugs to Thailand.

  AIDS policy & law 20070406

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

  Journal of acquired immune deficiency syndromes (1999) 20070401

• Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

  The Journal of infectious diseases 20070401

• Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors.

  Microbes and infection 20070401

• Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.

  European journal of haematology 20070401

• ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

  PLoS pathogens 20070401

• Lopinavir/ritonavir: appraisal of its use in HIV therapy.

  Drugs of today (Barcelona, Spain : 1998) 20070401

• Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients.

  AIDS patient care and STDs 20070401

• Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.

  AIDS (London, England) 20070330

• Antimalarial activity of sera from subjects taking HIV protease inhibitors.

  AIDS (London, England) 20070330

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.

  AIDS (London, England) 20070312

• [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].

  Medecine et maladies infectieuses 20070301

• Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070301

• Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

  Pharmacogenomics 20070301

• Thyrotoxic periodic paralysis in a Polynesian male following highly active antiretroviral therapy for HIV infection.

  Hawaii medical journal 20070301

• [Antiretrovirals].

  Nihon rinsho. Japanese journal of clinical medicine 20070227

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20070201

• Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

  Expert review of anti-infective therapy 20070201

• Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy.

  AJNR. American journal of neuroradiology 20070201

• Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.

  Therapeutic drug monitoring 20070201

• Induction therapy with enfuvirtide-based highly active antiretroviral therapy in a patient with acute HIV-1 infection.

  AIDS patient care and STDs 20070201

• Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced Brazilian children receiving highly active antiretroviral therapy containing lopinavir-ritonavir.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20070201

• Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.

  AIDS (London, England) 20070130

• Directed reductive amination of beta-hydroxy-ketones: convergent assembly of the ritonavir/lopinavir core.

  Organic letters 20070118

• Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.

  AIDS (London, England) 20070111

• Nifedipine-lopinavir/ritonavir severe interaction: a case report.

  AIDS (London, England) 20070102

• Hyponatraemia associated with lopinavir--ritonavir?

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20070101

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• Evaluation of 384-well formatted sample preparation technologies for regulated bioanalysis.

  Rapid communications in mass spectrometry : RCM 20070101

• The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis.

  International journal of antimicrobial agents 20070101

• Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.

  Clinical drug investigation 20070101

• Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

  Clinical pharmacology and therapeutics 20070101

• Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

  Clinical pharmacokinetics 20070101

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.

  HIV medicine 20070101

• Public health the leading force of the Indonesian response to the HIV/AIDS crisis among people who inject drugs.

  Harm reduction journal 20070101

• In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate.

  Retrovirology 20070101

• Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

  Antiviral therapy 20070101

• A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.

  Antiviral therapy 20070101

• Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone.

  HIV clinical trials 20070101

• Infections and immunosuppression as specific problems in a HIV + patient transplanted for end-stage alcoholic cirrhosis.

  Acta chirurgica Belgica 20070101

• TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?

  Globalization and health 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

  Clinical drug investigation 20070101

• Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

  Clinical drug investigation 20070101

• Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.

  Antiviral therapy 20070101

• Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.

  Antiviral therapy 20070101

• Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.

  Antiviral therapy 20070101

• Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.

  Scandinavian journal of infectious diseases 20070101

• Differential drug resistance acquisition in HIV-1 of subtypes B and C.

  PloS one 20070101

• Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

  Antiviral therapy 20070101

• High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.

  HIV clinical trials 20070101

• Comparison of lopinavir level between the two formulations (soft-gel capsule and tablet) in HIV-infected pregnant women.

  HIV clinical trials 20070101

• Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

  Clinical pharmacokinetics 20070101

• Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.

  Antiviral therapy 20070101

• Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.

  HIV clinical trials 20070101

• The association of bone mineral density with HIV infection and antiretroviral treatment in women.

  Antiviral therapy 20070101

• Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.

  Antiviral therapy 20070101

• Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.

  Clinical drug investigation 20070101

• Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

  BMC public health 20070101

• Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

  Cost effectiveness and resource allocation : C/E 20070101

• Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

  Current medicinal chemistry 20070101

• [Interruption to treatment with combined lopinavir/ritonavir therapy in HIV positive patients].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101

• Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

  The American journal on addictions 20070101

• Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.

  Antiviral therapy 20070101

• Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

  Antiviral therapy 20070101

• [Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20070101

• Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.

  The open virology journal 20070101

• Maraviroc: the evidence for its potential in the management of HIV.

  Core evidence 20070101

• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215

• Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.

  Journal of medicinal chemistry 20061214

• Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.

  Journal of medical virology 20061201

• [Histoplasmosis leading to diagnosis of HIV infection].

  Presse medicale (Paris, France : 1983) 20061201

• Better lipid profile for Invirase.

  AIDS patient care and STDs 20061201

• [Kaletra, a new anti HIV agent].

  Revue de l'infirmiere 20061201

• The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone.

  AIDS (London, England) 20061128

• Measuring below the bar: what is it telling us?

  AIDS (London, England) 20061128

• Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function.

  AIDS (London, England) 20061128

• Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

  AIDS (London, England) 20061114

• Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease.

  Antiviral research 20061101

• In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

  Antimicrobial agents and chemotherapy 20061101

• The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20061101

• Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

  PLoS medicine 20061101

• Does HIV cause cardiovascular disease?

  PLoS medicine 20061101

• Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.

  AIDS patient care and STDs 20061101

• Long-term immunologic outcome in HAART-experienced subjects receiving lopinavir/ritonavir.

  AIDS research and human retroviruses 20061101

• XVI International AIDS Conference: Part 2.

  The AIDS reader 20061101

• Report from the XVI International AIDS Conference. Lopinavir/ritonavir monotherapy.

  AIDS clinical care 20061101

• Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction.

  Journal of chromatography. A 20061020

• Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061015

• Reduced lopinavir exposure during pregnancy.

  AIDS (London, England) 20061003

• Response to 'Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?' by Hill.

  AIDS (London, England) 20061003

• Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.

  Bioorganic & medicinal chemistry 20061001

• A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

  Journal of acquired immune deficiency syndromes (1999) 20061001

• [Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients].

  Enfermedades infecciosas y microbiologia clinica 20061001

• Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.

  Clinical pharmacology and therapeutics 20061001

• A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults.

  Therapeutic drug monitoring 20061001

• Abbott expands low cost Kaletra.

  AIDS patient care and STDs 20061001

• Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.

  AIDS (London, England) 20060911

• Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060901

• The urological management of the patient with acquired immunodeficiency syndrome.

  BJU international 20060901

• The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.

  British journal of clinical pharmacology 20060901

• SARS: systematic review of treatment effects.

  PLoS medicine 20060901

• Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs.

  AIDS (London, England) 20060822

• Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.

  AIDS (London, England) 20060822

• The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.

  Lancet (London, England) 20060805

• Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.

  The Journal of antimicrobial chemotherapy 20060801

• Qualitative and quantitative analysis of pharmaceutical compounds by MALDI-TOF mass spectrometry.

  Analytical chemistry 20060801

• Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.

  Therapeutic drug monitoring 20060801

• Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects.

  Clinical pharmacology and therapeutics 20060801

• Kaletra approval in Europe.

  AIDS patient care and STDs 20060801

• Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.

  AIDS research and human retroviruses 20060801

• Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion.

  European journal of medical research 20060731

• Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model.

  American journal of obstetrics and gynecology 20060701

• Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.

  Pediatric nephrology (Berlin, Germany) 20060701

• Time-dependent interaction between lopinavir/ritonavir and fexofenadine.

  Journal of clinical pharmacology 20060701

• Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

  HIV medicine 20060701

• Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

  European journal of medical research 20060630

• Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060615

• Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.

  Antiviral research 20060601

• Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

  The Journal of antimicrobial chemotherapy 20060601

• Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects.

  The Journal of infectious diseases 20060601

• Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

  The Annals of pharmacotherapy 20060601

• Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?

  Therapeutic drug monitoring 20060601

• FDA notifications. HIV-1 adult treatment guidelines are updated.

  AIDS alert 20060601

• Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.

  AIDS (London, England) 20060512

• Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient.

  AIDS (London, England) 20060512

• Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

  Biochemistry 20060502

• Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

  The Journal of general virology 20060501

• Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.

  Journal of acquired immune deficiency syndromes (1999) 20060501

• Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20060501

• Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

  AIDS (London, England) 20060424

• The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.

  AIDS (London, England) 20060424

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Plasma and cerebrospinal pharmacokinetics and pharmacodynamics in subjects taking lopinavir/ritonavir.

  AIDS (London, England) 20060424

• Do the mutations M046I and I047A confer resistance to kaletra?

  AIDS (London, England) 20060404

• Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study).

  Atherosclerosis 20060401

• Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060401

• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  Bioorganic & medicinal chemistry letters 20060401

• Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20060401

• Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients.

  HIV medicine 20060401

• Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.

  Therapeutic drug monitoring 20060401

• Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support.

  Journal of acquired immune deficiency syndromes (1999) 20060401

• Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.

  Journal of acquired immune deficiency syndromes (1999) 20060401

• [When Doctors Without Borders writes to Miles White, chairman of Abbott Laboratories].

  Revue medicale suisse 20060329

• MDR- and CYP3A4-mediated drug-herbal interactions.

  Life sciences 20060327

• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

  AIDS (London, England) 20060321

• Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060320

• Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency.

  The Journal of antimicrobial chemotherapy 20060301

• Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment.

  Journal of clinical pharmacology 20060301

• In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

  Antimicrobial agents and chemotherapy 20060301

• Sometimes intermediates. Do the job!

  Chemistry & biology 20060301

• Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.

  Therapeutic drug monitoring 20060201

• Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.

  AIDS research and human retroviruses 20060201

• Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core.

  Organic letters 20060105

• High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

  AIDS (London, England) 20060102

• Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study.

  AIDS (London, England) 20060102

• Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.

  Biomedical chromatography : BMC 20060101

• Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder.

  The Annals of pharmacotherapy 20060101

• [HIV infection presenting with bilateral optic neuropathy].

  Revue neurologique 20060101

• [Antiretroviral drugs in severe acute respiratory syndrome].

  Presse medicale (Paris, France : 1983) 20060101

• Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.

  Antiviral therapy 20060101

• Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

  Antiviral therapy 20060101

• Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma.

  Clinical chemistry and laboratory medicine 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy.

  Antiviral therapy 20060101

• Three-year final results of the NEFA simplification trial.

  AIDS reviews 20060101

• [Role of bone gammagraphy in the diagnosis of secondary osteomalacia in a patient treated with tenofovir].

  Revista espanola de medicina nuclear 20060101

• A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.

  Rapid communications in mass spectrometry : RCM 20060101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20060101

• Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

  BMC infectious diseases 20060101

• Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.

  Antiviral therapy 20060101

• Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.

  Antiviral therapy 20060101

• Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy.

  Antiviral therapy 20060101

• Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.

  Scandinavian journal of infectious diseases 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• HIV-2 Protease resistance defined in yeast cells.

  Retrovirology 20060101

• Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.

  Antiviral therapy 20060101

• Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.

  Antiviral therapy 20060101

• Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

  HIV clinical trials 20060101

• Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin.

  Antiviral chemistry & chemotherapy 20060101

• A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy.

  HIV clinical trials 20060101

• Detection of a proteasome in Pneumocystis carinii and its modulation by specific proteasome inhibitors.

  The Journal of eukaryotic microbiology 20060101

• Substitution with lopinavir/ritonavir improves patient-reported outcomes including quality of life in patients who were intolerant to their antiretroviral therapy.

  HIV clinical trials 20060101

• Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.

  HIV clinical trials 20060101

• Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.

  HIV clinical trials 20060101

• Drug interactions. Brecanavir--a new protease inhibitor.

  TreatmentUpdate 20060101

• Drug interactions. Coming soon--a new formulation of Kaletra.

  TreatmentUpdate 20060101

• Drug interactions. Kaletra and ezetimibe.

  TreatmentUpdate 20060101

• Drug interactions. Kaletra and atazanavir.

  TreatmentUpdate 20060101

• The state of access to Kaletra.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20060101

• LPV monotherapy: 72-week data.

  IAPAC monthly 20060101

• Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.

  Antiviral therapy 20060101

• Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227

• Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

  Bioorganic & medicinal chemistry letters 20051215

• Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

  The Journal of antimicrobial chemotherapy 20051201

• Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.

  Journal of acquired immune deficiency syndromes (1999) 20051201

• Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients.

  Therapeutic drug monitoring 20051201

• No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.

  Therapeutic drug monitoring 20051201

• Ritonavir and lopinavir/ritonavir package inserts are updated.

  AIDS alert 20051201

• FDA notifications. FDA approves new Kaletra formulation.

  AIDS alert 20051201

• [Protease inhibitors].

  Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20051201

• Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan.

  AIDS (London, England) 20051118

• Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

  AIDS (London, England) 20051118

• Long-term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART-experienced subjects: 4 year follow-up study.

  AIDS (London, England) 20051104

• In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051101

• Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

  Journal of acquired immune deficiency syndromes (1999) 20051101

• The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.

  HIV medicine 20051101

• Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20051101

• Antiretroviral treatment in the Northern Cape.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20051101

• Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051015

• Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

  The Journal of infectious diseases 20051015

• MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells.

  AIDS (London, England) 20051014

• Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20051001

• Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.

  British journal of clinical pharmacology 20051001

• Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

  The Pediatric infectious disease journal 20051001

• Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.

  The Pediatric infectious disease journal 20051001

• Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

  Current medical research and opinion 20051001

• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  Current drug metabolism 20051001

• Meeting notes from the 3rd IAS Conference. Old drugs, new data.

  AIDS clinical care 20051001

• Focus on hepatitis. Low rate of liver problems seen with LPV/r.

  IAPAC monthly 20051001

• Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS.

  AIDS (London, England) 20050923

• The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals.

  AIDS (London, England) 20050902

• Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.

  AIDS (London, England) 20050902

• Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients.

  The Journal of antimicrobial chemotherapy 20050801

• Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.

  Bioorganic & medicinal chemistry letters 20050801

• Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.

  The Journal of antimicrobial chemotherapy 20050801

• Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050801

• Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection.

  Expert opinion on pharmacotherapy 20050801

• Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.

  AIDS research and human retroviruses 20050801

• Instability of lopinavir/ritonavir capsules at ambient temperatures in sub-Saharan Africa: relevance to WHO antiretroviral guidelines.

  AIDS (London, England) 20050722

• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.

  International journal of antimicrobial agents 20050701

• Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

  The Journal of antimicrobial chemotherapy 20050701

• Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.

  Protein science : a publication of the Protein Society 20050701

• Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.

  AIDS (London, England) 20050701

• Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz.

  British journal of clinical pharmacology 20050701

• Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20050701

• Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.

  Biological & pharmaceutical bulletin 20050701

• Once-daily Kaletra approved.

  AIDS patient care and STDs 20050701

• Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.

  The Journal of infectious diseases 20050615

• Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

  AIDS (London, England) 20050610

• Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

  The Journal of antimicrobial chemotherapy 20050601

• Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

  Therapeutic drug monitoring 20050601

• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

  Antimicrobial agents and chemotherapy 20050601

• Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.

  Antimicrobial agents and chemotherapy 20050601

• FDA approves once-daily Kaletra.

  The AIDS reader 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525

• Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

  AIDS (London, England) 20050520

• Oximinoarylsulfonamides as potent HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050502

• Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

  The Journal of antimicrobial chemotherapy 20050501

• Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children.

  Journal of acquired immune deficiency syndromes (1999) 20050501

• Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children.

  AIDS research and human retroviruses 20050501

• Safety of lopinavir/ritonavir for the treatment of HIV-infection.

  Expert opinion on drug safety 20050501

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050429

• [First-line monotherapy with boostered protease inhibitor. Effectively reduce viral load with only one drug?].

  MMW Fortschritte der Medizin 20050425

• [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].

  MMW Fortschritte der Medizin 20050425

• [HIV therapy in childhood. Also once daily lopinavir/r is effective].

  MMW Fortschritte der Medizin 20050425

• [Efavirenz--comprehensive status of studies].

  MMW Fortschritte der Medizin 20050425

• [New data on atazanavir/r]].

  MMW Fortschritte der Medizin 20050425

• A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.

  European journal of clinical pharmacology 20050401

• Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models.

  Journal of clinical pharmacology 20050401

• Lopinavir/ritonavir combination and total/HDL cholesterol ratio.

  The Journal of infection 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.

  British journal of clinical pharmacology 20050401

• Lopinavir/r versus nelfinavir as salvage therapy.

  The Pediatric infectious disease journal 20050401

• [Meningeal cryptococcosis as a sign of immune reconstitution syndrome].

  Enfermedades infecciosas y microbiologia clinica 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

  Journal of medicinal chemistry 20050324

• Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.

  AIDS (London, England) 20050304

• Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050301

• Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

  Journal of acquired immune deficiency syndromes (1999) 20050301

• Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.

  Expert opinion on drug safety 20050301

• Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.

  HIV medicine 20050301

• Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

  The Journal of pharmacology and experimental therapeutics 20050201

• Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients.

  The Journal of antimicrobial chemotherapy 20050201

• Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.

  British journal of clinical pharmacology 20050201

• Blockade of HERG channels by HIV protease inhibitors.

  Lancet (London, England) 20050201

• Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

  AIDS (London, England) 20050128

• Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

  AIDS (London, England) 20050128

• Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines.

  The Journal of biological chemistry 20050121

• Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050115

• Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).

  Journal of acquired immune deficiency syndromes (1999) 20050101

• Acquired macroglossia due to lopinavir/ritonavir treatment.

  Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20050101

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.

  Annals of clinical microbiology and antimicrobials 20050101

• Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.

  International journal of immunopathology and pharmacology 20050101

• Boosted Reyataz comparable to Kaletra.

  AIDS patient care and STDs 20050101

• Top stories of 2004. Back to the future: lopinavir/ritonavir as 'monotherapy'.

  AIDS clinical care 20050101

• Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.

  Drugs 20050101

• Early virological failure with a combination of tenofovir, didanosine and efavirenz.

  Antiviral therapy 20050101

• Maculo-papular rash induced by lopinavir/ritonavir.

  European journal of dermatology : EJD 20050101

• Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.

  Acta virologica 20050101

• [Assessment of renal abnormalities in 107 HIV patients treated with tenofovir].

  Therapie 20050101

• Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

  HIV clinical trials 20050101

• Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

  HIV clinical trials 20050101

• Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

  BMC infectious diseases 20050101

• Drug-drug interactions and the pharmacotherapy of HIV infection.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

  Antiviral therapy 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.

  Antiviral therapy 20050101

• Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

  International journal of immunopathology and pharmacology 20050101

• Anti-HIV agents. Kaletra + atazanavir.

  TreatmentUpdate 20050101

• Anti-HIV agents. Kaletra and Meltrex update.

  TreatmentUpdate 20050101

• Anti-HIV agents. Atazanavir vs. Kaletra.

  TreatmentUpdate 20050101

• Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.

  Journal of immunological methods 20041201

• Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

  PLoS medicine 20041201

• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

  Antiviral therapy 20041201

• International AIDS Conference: compliance issues.

  AIDS (London, England) 20041119

• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

  AIDS (London, England) 20041119

• First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.

  AIDS (London, England) 20041119

• Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.

  Journal of medicinal chemistry 20041118

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

  AIDS (London, England) 20041105

• Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101

• Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.

  The Journal of antimicrobial chemotherapy 20041101

• Lopinavir plasma levels in salvage regimes by a population of highly active antiretroviral therapy-treated HIV-1-positive patients.

  AIDS patient care and STDs 20041101

• Pharmacokinetics of Telzir (fosamprenavir).

  Journal of HIV therapy 20041101

• [Therapeutic strategies for HIV infection: clinical approach with boost antiproteases in adults].

  Medecine et maladies infectieuses 20041101

• [Therapeutic strategies for HIV infection: tolerance to boost antiproteases].

  Medecine et maladies infectieuses 20041101

• Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015

• Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20041001

• Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.

  Therapeutic drug monitoring 20041001

• Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.

  Therapeutic drug monitoring 20041001

• The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.

  Antiviral therapy 20041001

• Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20041001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041001

• Hepatitis coinfection and LPV/RTV.

  IAPAC monthly 20041001

• Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

  AIDS (London, England) 20040924

• Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.

  AIDS (London, England) 20040924

• Kaletra monotherapy controversy: AmfAR publishes overview.

  AIDS treatment news 20040924

• Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients.

  Journal of medical virology 20040901

• In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040901

• Lopinavir/ritonavir- and indinavir-induced thrombocytopenia in a patient with HIV infection.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20040901

• Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

  HIV medicine 20040901

• Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans.

  Pharmaceutical research 20040901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040901

• Lopinavir monotherapy effective.

  AIDS patient care and STDs 20040901

• Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction.

  Journal of acquired immune deficiency syndromes (1999) 20040815

• Lipid abnormalities in HIV-Infected patients and lopinavir plasma concentrations.

  Journal of acquired immune deficiency syndromes (1999) 20040815

• Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.

  The Journal of antimicrobial chemotherapy 20040801

• Advancements in the battle against severe acute respiratory syndrome.

  Expert opinion on pharmacotherapy 20040801

• Resistance to HIV protease inhibitors: mechanisms and clinical consequences.

  Current drug metabolism 20040801

• The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

  Antiviral therapy 20040801

• Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.

  Antiviral therapy 20040801

• Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

  Antiviral therapy 20040801

• Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

  The Journal of infectious diseases 20040715

• Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20040701

• Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection.

  AIDS research and human retroviruses 20040701

• Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).

  AIDS (London, England) 20040618

• High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

  Pharmacotherapy 20040601

• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

  Antiviral therapy 20040601

• Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

  Antiviral therapy 20040601

• Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance.

  Antiviral therapy 20040601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• Novel lopinavir analogues incorporating heterocyclic replacements of six-member cyclic urea--synthesis and structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20040517

• Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs.

  Bioorganic & medicinal chemistry 20040515

• [New treatment options for HIV-infected patients].

  Deutsche medizinische Wochenschrift (1946) 20040507

• HIV protease inhibitors increase adiponectin levels in HIV-negative men.

  Journal of acquired immune deficiency syndromes (1999) 20040501

• Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient.

  AIDS (London, England) 20040430

• [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].

  MMW Fortschritte der Medizin 20040426

• [From HAART to 'smart': maximizing the advantages of lopinavir/ritonavir].

  MMW Fortschritte der Medizin 20040426

• [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].

  MMW Fortschritte der Medizin 20040426

• [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].

  MMW Fortschritte der Medizin 20040426

• [Lopinavir: also effective using once daily dose in therapy-naive HIV patients].

  Deutsche medizinische Wochenschrift (1946) 20040416

• Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040415

• Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.

  British journal of clinical pharmacology 20040401

• Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.

  Antiviral research 20040401

• Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040401

• Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040401

• Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.

  Infection 20040401

• Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.

  Clinical pharmacology and therapeutics 20040401

• Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

  Antiviral therapy 20040401

• IQ predicts treatment response.

  AIDS patient care and STDs 20040401

• Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.

  AIDS (London, England) 20040326

• The longer the better? Four years of durable, initially boosted protease treatment.

  AIDS (London, England) 20040326

• The metabolic effects of lopinavir/ritonavir in HIV-negative men.

  AIDS (London, England) 20040305

• Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases.

  AIDS (London, England) 20040305

• Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.

  The Journal of antimicrobial chemotherapy 20040301

• Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

  Thorax 20040301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040301

• Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrations.

  Journal of acquired immune deficiency syndromes (1999) 20040301

• Changes in Kaletra labelling.

  AIDS patient care and STDs 20040301

• Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.

  AIDS research and human retroviruses 20040301

• Anti-HIV agents. Once-daily lopinavir/ritonavir (Kaletra).

  TreatmentUpdate 20040301

• Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

  AIDS (London, England) 20040220

• Lopinavir protein binding in vivo through the 12-hour dosing interval.

  Therapeutic drug monitoring 20040201

• Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers.

  Biological & pharmaceutical bulletin 20040201

• SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.

  Hepatology (Baltimore, Md.) 20040201

• FDA notifications. UCB Pharma and FDA issue advisory letter.

  AIDS alert 20040201

• Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.

  Antiviral therapy 20040201

• Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children.

  AIDS (London, England) 20040123

• Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

  The Journal of infectious diseases 20040115

• Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20040102

• Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.

  AIDS (London, England) 20040102

• Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

  The Journal of infectious diseases 20040101

• A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.

  HIV medicine 20040101

• Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.

  International journal of STD & AIDS 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.

  AIDS patient care and STDs 20040101

• Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.

  Journal of molecular recognition : JMR 20040101

• Pharmacokinetic enhancement of protease inhibitor therapy.

  Clinical pharmacokinetics 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Recurrent oedema associated with the co-formulation of lopinavir and ritonavir.

  Revista da Sociedade Brasileira de Medicina Tropical 20040101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Backlash over ritonavir price hike.

  BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20040101

• Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

  Clinical pharmacokinetics 20040101

• Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

  HIV clinical trials 20040101

• Pharmacokinetics of antiretrovirals in pregnant women.

  Clinical pharmacokinetics 20040101

• Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).

  HIV clinical trials 20040101

• Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

  Scandinavian journal of infectious diseases 20040101

• Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir.

  TreatmentUpdate 20040101

• Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031215

• [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].

  MMW Fortschritte der Medizin 20031211

• [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].

  MMW Fortschritte der Medizin 20031211

• No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.

  European journal of medical research 20031209

• Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir.

  Pharmacology 20031201

• Tacrolimus and lopinavir/ritonavir interaction in liver transplantation.

  The Annals of pharmacotherapy 20031201

• Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir.

  International journal of antimicrobial agents 20031201

• Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.

  Hong Kong medical journal = Xianggang yi xue za zhi 20031201

• Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

  Dermatology online journal 20031201

• French investigators warn of LPV/TDF/ddI interaction.

  IAPAC monthly 20031201

• Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.

  Biochemistry 20031125

• Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir.

  AIDS (London, England) 20031107

• Treating advanced HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20031101

• New patterns of HIV-1 resistance during HAART.

  Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20031101

• SARS: pharmacotherapy.

  Respirology (Carlton, Vic.) 20031101

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20031001

• Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy.

  HIV medicine 20031001

• Diarrhea related to lopinavir is most often mild and not related to plasma drug levels.

  Journal of acquired immune deficiency syndromes (1999) 20031001

• More data released on 908.

  AIDS patient care and STDs 20031001

• HCV snapshots: macro to micro.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20031001

• Atazanavir (Reyataz).

  Project Inform perspective 20031001

• The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.

  Expert review of anti-infective therapy 20031001

• Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.

  The Journal of antimicrobial chemotherapy 20030901

• Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

  The Journal of antimicrobial chemotherapy 20030901

• Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks.

  The Journal of infectious diseases 20030901

• In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

  Antimicrobial agents and chemotherapy 20030901

• Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20030901

• Severe acute respiratory syndrome: Relapse? Hospital infection?

  Emerging infectious diseases 20030901

• Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.

  AIDS patient care and STDs 20030901

• Boosted PIs: competition hots up.

  The AIDS reader 20030901

• Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.

  AIDS clinical care 20030901

• Kaletra goes it alone.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20030901

• [Resistance of HIV-1 to antiretroviral drugs in Valencia (Spain): mutations and susceptibility].

  Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia 20030901

• The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030815

• HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience.

  Journal of acquired immune deficiency syndromes (1999) 20030801

• Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir.

  Antiviral research 20030801

• [Lopinavir/r in new packaging].

  Deutsche medizinische Wochenschrift (1946) 20030801

• Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy.

  AIDS (London, England) 20030725

• Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient.

  AIDS (London, England) 20030725

• Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.

  International journal of antimicrobial agents 20030701

• pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.

  AIDS research and human retroviruses 20030701

• Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors.

  Journal of immunology (Baltimore, Md. : 1950) 20030615

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz.

  Chemical & pharmaceutical bulletin 20030601

• Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.

  Antiviral therapy 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.

  AIDS (London, England) 20030523

• Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.

  AIDS (London, England) 20030502

• Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.

  AIDS (London, England) 20030502

• Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.

  AIDS (London, England) 20030502

• Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.

  AIDS (London, England) 20030502

• Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?

  Atherosclerosis 20030501

• Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

  Seminars in liver disease 20030501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20030501

• Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.

  AIDS patient care and STDs 20030501

• Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.

  AIDS patient care and STDs 20030501

• [Justified hope after 4 years. Initial therapy still without resistance].

  MMW Fortschritte der Medizin 20030428

• [Results of a large randomized study: after switch to LPV/r quality of life improved].

  MMW Fortschritte der Medizin 20030428

• ['Double boosting' passes the test. LPV/r plus SQV in complicated salvage situation].

  MMW Fortschritte der Medizin 20030428

• Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425

• Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030415

• Phase II clinical trials of Kaletra.

  AIDS (London, England) 20030411

• HIV-1 RNA levels, resistance, and drug diffusion in semen versus blood in patients receiving a lopinavir-containing regimen.

  Journal of acquired immune deficiency syndromes (1999) 20030401

• The safety and tolerability of switching from a non-failing antiretroviral regimen to lopinavir.

  The Journal of infection 20030401

• Cushing's syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone.

  HIV medicine 20030401

• Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.

  AIDS (London, England) 20030328

• Determining the relative efficacy of highly active antiretroviral therapy.

  The Journal of infectious diseases 20030315

• Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

  Journal of acquired immune deficiency syndromes (1999) 20030301

• Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20030301

• [First evaluations of LPV/RTV (Kaletra) efficacy on HIV-positive patients treated with multiple drugs].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20030301

• Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.

  The Journal of pharmacy and pharmacology 20030301

• Gateways to clinical trials. March 2003.

  Methods and findings in experimental and clinical pharmacology 20030301

• 'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.

  Contact dermatitis 20030301

• Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• The efficacy of lopinavir in individuals experiencing protease inhibitor failure.

  Journal of acquired immune deficiency syndromes (1999) 20030201

• Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of mass spectrometry : JMS 20030201

• Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030201

• Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

• Lopinavir/ritonavir absorption in a gastrectomized patient.

  AIDS (London, England) 20030103

• Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.

  The Journal of antimicrobial chemotherapy 20030101

• Protease inhibitor shown to hold HIV at undetectable levels.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20030101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20030101

• Kidney damage reported in some tenofovir users.

  TreatmentUpdate 20030101

• Saquinavir: a review of its use in boosted regimens for treating HIV infection.

  Drugs 20030101

• Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.

  HIV clinical trials 20030101

• Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients.

  HIV clinical trials 20030101

• A Comparison of the Therapeutic Plan Costs in the Treatment of HIV-Positive Patients.

  Clinical drug investigation 20030101

• Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.

  International journal of antimicrobial agents 20021201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021201

• Epoxyalcohol route to hydroxyethylene dipeptide isosteres. Stereodivergent synthesis of the diamino alcohol core of ritonavir and its C-2 epimer.

  The Journal of organic chemistry 20021129

• Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy.

  AIDS (London, England) 20021122

• Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships.

  Bioorganic & medicinal chemistry letters 20021104

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.

  AIDS (London, England) 20021018

• [Complete auriculoventricular block in a patient treatment with Lopinavir/Ritonavir].

  Enfermedades infecciosas y microbiologia clinica 20021001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20021001

• Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.

  AIDS research and human retroviruses 20020920

• Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

  Antiviral therapy 20020901

• Limited penetration of lopinavir into seminal plasma of HIV-1-infected men.

  AIDS (London, England) 20020816

• Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020815

• Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.

  Journal of acquired immune deficiency syndromes (1999) 20020815

• Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020805

• X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

  Bioorganic & medicinal chemistry 20020801

• Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20020801

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715

• In vitro antiviral interaction of lopinavir with other protease inhibitors.

  Antimicrobial agents and chemotherapy 20020701

• Increasing choices for HIV therapy.

  The New England journal of medicine 20020627

• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  The New England journal of medicine 20020627

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• [When nucleoside analogs cannot be tolerated. HIV therapy with booster].

  MMW Fortschritte der Medizin 20020509

• Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

  AIDS (London, England) 20020503

• Synthesis and structure-activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir).

  Bioorganic & medicinal chemistry letters 20020422

• Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020415

• Transplacental passage of protease inhibitors at delivery.

  AIDS (London, England) 20020412

• [After 3 years no resistance development. Protease inhibitor with staying power].

  MMW Fortschritte der Medizin 20020409

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

  AIDS (London, England) 20020329

• Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.

  AIDS (London, England) 20020329

• Inflammatory oedema associated with lopinavir-including HAART regimens in advanced HIV-1 infection: report of 3 cases.

  AIDS (London, England) 20020308

• Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.

  The Journal of infectious diseases 20020301

• Lopinavir/ritonavir (ABT-378/r).

  Expert opinion on pharmacotherapy 20020301

• Efavirenz-induced skin eruption and successful desensitization.

  The Annals of pharmacotherapy 20020301

• Drug resistance test shows encouraging results.

  AIDS alert 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

  AIDS (London, England) 20020125

• Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

  HIV clinical trials 20020101

• Encouraging resistance data for Kaletra (lopinavir/ritonavir).

  The Journal of the Association of Nurses in AIDS Care : JANAC 20020101

• Delavirdine in rescue regimens.

  TreatmentUpdate 20020101

• Kaletra (lopinavir/ritonavir).

  The Annals of pharmacotherapy 20020101

• [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ].

  Therapie 20020101

• Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families.

  HIV clinical trials 20020101

• [Kaletra (lopinavir/ritonavir--a new HIV protease inhibitor].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20020101

• Ototoxicity may be associated with protease inhibitor therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215

• Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.

  Therapeutic drug monitoring 20011201

• Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

  Antiviral therapy 20011201

• Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.

  AIDS (London, England) 20011123

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.

  Antimicrobial agents and chemotherapy 20011101

• Lopinavir-Ritonavir: a new protease inhibitor.

  Pharmacotherapy 20011101

• What's new: newly approved drugs for children.

  Pediatrics in review 20011001

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy.

  AIDS (London, England) 20010615

• Antiretroviral approved for use in infants.

  American family physician 20010615

• Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).

  Bioorganic & medicinal chemistry letters 20010604

• Resistant to everything.

  AIDS clinical care 20010501

• Inflammatory oedema of the legs: a new side-effect of lopinavir.

  AIDS (London, England) 20010413

• [No resistance even after 1 year. New drug combination against HIV].

  MMW Fortschritte der Medizin 20010402

• [Overcoming weaknesses in therapy. Protease inhibitors with high IQ].

  MMW Fortschritte der Medizin 20010402

• [An option even for patients with multiple pretreatment].

  MMW Fortschritte der Medizin 20010402

• Principles and practice of HIV-protease inhibitor pharmacoenhancement.

  HIV medicine 20010401

• ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis.

  AIDS (London, England) 20010330

• [HIV: a guide on management of seropositive patients].

  Presse medicale (Paris, France : 1983) 20010303

• Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.

  Clinical therapeutics 20010301

• Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase.

  Bioorganic & medicinal chemistry letters 20010212

• Lopinavir/ritonavir: a protease inhibitor combination.

  The Medical letter on drugs and therapeutics 20010108

• ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

  AIDS (London, England) 20010105

• Lopinavir/ritonavir.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Kaletra approved in Canada.

  TreatmentUpdate 20010101

• Kaletra versus nelfinavir.

  TreatmentUpdate 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• The importance of sequencing in treatment options.

  Positively aware : the monthly journal of the Test Positive Aware Network 20010101

• Newest protease inhibitor Kaletra has a unique profile.

  HIV clinician 20010101

• Kaletra: applying advances in pharmacokinetics to treating HIV.

  HIV clinician 20010101

• Combination drug approved to treat HIV.

  FDA consumer 20010101

• New drug approvals in 2000.

  General dentistry 20010101

• Anti-HIV agents. Lopinavir--results after one year.

  TreatmentUpdate 20010101

• New drugs.

  The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20010101

• Protease inhibitors: current status and future prospects.

  Journal of medicinal chemistry 20000210

• ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

  Antimicrobial agents and chemotherapy 19981201

• Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

  Virology 19981025

• In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor.

  Journal of virology 19980901